▎Edited by the WuXi AppTec content team
According to incomplete statistics from Innovation Radar, last week (March 18 to March 24) in the global health sectorA total of 37 financing events were disclosed, with a total amount of nearly 10.5 billion yuan.. In terms of amount, there were 15 financings of 100 million yuan or more.According to the disclosed financing rounds, there were 21 early-stage financings (before Series B) and 9 mid-to-late stage financings (Series B and later).Start.13 Companies in the Biopharmaceutical Field Receive Financing, Involving Drug Types Including CAR-T Cell Therapy,Allosteric agents, bispecific antibodies, gene therapyetc.
#01
Mirador Therapeutics Completes Over $400 Million Series A Financing
Keywords: Precision Therapies for Immune-Mediated DiseasesLatest Financing:Over $400 Million Series AThis round of investment institutions: OrbiMed, Sanofi Ventures, Alexandria Venture Investments, ARCH Venture Partners, Blue Owl Healthcare Opportunities, etc.March 20Mirador Therapeutics announced its emergence from stealth mode and completion of over $400 million in financing. MiradorAiming to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases by rapidly advancing multiple projects through the use of its proprietary Mirador360 development engine.Mirador’s proprietary Mirador360 platform combines the latest breakthroughs in human genetics and cutting-edge data science to analyze the molecular profiles of millions of patients. It discovers and validates genetic information related to immune fibrosis diseases, identifies new therapeutic targets, clarifies interactions between targets, and uncovers optimal target pairings for potential combination therapies. Additionally, Mirador360 assists Mirador in developing diagnostic tests and stratifying patient populations to achieve precise clinical development.
#02
Capstan Therapeutics Completes $175 Million Series B Financing
Keywords：CAR-T Cell TherapyLatest Financing:$175 Million Series BThis round of investment institutions: OrbiMed, Bristol-Myers Squibb, Pfizer Ventures, Eli Lilly and Company, RA Capital Management, etc.On March 20, Capstan Therapeutics announced the completion of a $175 million Series B financing. The funds obtained from the Series B financing will be used forAdvance the early clinical concept validation of Capstan Therapeutics' lead in vivo chimeric antigen receptor T-cell (CAR-T) candidate therapy, CPTX2309, in autoimmune diseases, and further develop Capstan's targeted lipid nanoparticle (tLNP) pipeline.。Capstan Therapeutics is dedicated to the development of cell therapies.CPTX2309 is a product of Capstan Therapeutics' tLNP platform. It delivers mRNA payloads encoding chimeric antigen receptors targeting CD19 to CD8-expressing T cells, effectively generating CAR-T cell therapy directly in vivo. This approach aims to reset the immune system by achieving rapid and deep depletion of B cells in the blood and lymphoid tissues, while avoiding the challenges associated with traditional ex vivo production of CAR-T cell therapies.
#03
Engrail Therapeutics Completes $157 Million Series B Financing
Keywords: Allosteric agentLatest Financing:$157 Million Series BThis round of investment institutions: Pivotal Life Sciences, Red Tree Venture Capital, RiverVest Venture Partners, Ysios Capital, Eight Roads Capital, etc.March 20,Engrail Therapeutics Announces Oversubscribed $157 Million Series B FinancingThe proceeds from this round of financing will advance the company's R&D pipeline through multiple clinical development stages. The companyTherapies for treating diseases with significant unmet medical needs, including anxiety disorders, depression, post-traumatic stress disorder, and rare neurodegenerative diseases, are under development.。Its lead therapy, ENX-102, is a next-generation precision-targeted GABAA positive allosteric modulator (PAM) for the treatment of generalized anxiety disorder (GAD).ENX-102 aims to achieve long-lasting efficacy through long-term administration, while maintaining good safety and tolerability.
#04
Capstan Therapeutics Completes $150 Million Series A Financing
Keywords: Bispecific AntibodyLatest Financing:$150 Million Series AThis round of investment institutions: Alexandria Venture Investments, Blackbird Ventures, Catalio Capital Management, Cure Ventures, Novo Holdings, etc.On March 20, Clasp Therapeutics announced its emergence from stealth mode and the completion of a $150 million Series A financing round.The development of Clasp therapy is primarily based on the research achievements of its scientific co-founders, Dr. Bert Vogelstein and Dr. Drew Pardoll, professors at Johns Hopkins University. Their structural understanding of human leukocyte antigen (HLA)-antibody interactions has enabled them to perform molecular engineering on a new generation of T-cell engagers (TCE), allowing for precise targeting of common oncogenic mutations. ClaspFocused on developing modular T-cell engagers tailored to each patient's immune systemThese TCEs are off-the-shelf, bispecific antibody-like molecules designed to simultaneously target the CD3 protein on the surface of T cells and tumor-specific mutant peptides on the surface of cancer cells, thereby promoting T-cell attacks on cancer cells.
#05
Capstan Therapeutics Officially Listed on HKEX
Latest Financing:HK$239 million IPOCapstan Therapeutics officially listed on the Hong Kong Stock Exchange on March 20. The company, founded in 2015, focuses on developing biological therapies for treating autoimmune and allergic diseases. According to Capstan Therapeutics' prospectus, the companyThe product pipeline covers four major areas of autoimmune and allergic diseases, including skin, rheumatology, respiratory, and gastrointestinal diseases.The company has two core products —— IL-17A inhibitor QX002N and anti-IL-4Rα monoclonal antibody QX005N, which are currently in Phase 3 and Phase 2 clinical trials respectively. In addition, the company has seven other drug candidates at various stages of research. According to the prospectus of Capstan Therapeutics, the company plans to focus on advancing a broad drug pipeline in the short term, with dermatology as the priority area, while also advancing drug candidates for rheumatology, respiratory diseases, and gastrointestinal diseases. Capstan Therapeutics will also pursue commercial collaborations with other pharmaceutical companies and seek international commercial opportunities to accelerate the availability of its products for patients worldwide.
#06
Mirador Therapeutics Completes Pre-A+ Round Financing Worth Tens of Millions of Yuan
Latest Financing:Tens of Millions of Yuan in Pre-A+ RoundThis round of investment institutions: Hefei Innovation Investment, Cowind Venture CapitalOn March 19, Capstan Therapeutics announced the completion of a Pre-A+ round of financing worth tens of millions of RMB. The funds from this round will be used by the company...Initiate Phase 1/2 clinical trials for the wet age-related macular degeneration (wAMD) pipeline product, and advance the pharmaceutical, preclinical, and IIT clinical studies for the dry age-related macular degeneration (dAMD) pipeline.Capstan Therapeutics was founded in 2019 as a company focused on developing cutting-edge gene editing technologies and gene therapy products for ophthalmic diseases. The company is committed to advancing the application of gene therapy in ophthalmic indications, with ophthalmology as the breakthrough point, particularly targeting common eye diseases such as age-related macular degeneration (AMD). Capstan Therapeutics' self-developed gene therapy innovative drug, XMVA09 injection, has already been approved for clinical trials in China and is being developed for wet AMD. This is a gene therapy drug that combines dual-specificity targets with an intravitreal injection capsid.Readers, please star ⭐Chuangjianhui to receive updates第一时间收到推送.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress of global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction or distribution by media or institutions in any form to other platforms is strictly prohibited. For authorization to reproduce, please contact"InnoView"Contact us via the WeChat Official Account.
More Data Content RecommendationsClick "InSee", Sharing New Health Trends from Jianjianhui
